Reported Sunday, Genentech’s Divarasib Lowers Death Risk 44% In Phase III Krascendo 1 With Fewer TRAE Discontinuations (4.8% Versus 11.7%) Than Sotorasib Or Adagrasib In Previously Treated KRAS G12C NSCLC
Benzinga·10/26/2026 07:28:50
语音播报
- Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study
- At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib
- No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly low grade and manageable
- Data presented as a late-breaking abstract during a Presidential Symposium at the 2026 ESMO Congress and simultaneously published in The New England Journal of Medicine